News

The model may help clinicians enact preventative measures for those with migraine with aura at an early stage.

These data confirm the need for consideration of these costs when prescribing treatments, and is of considerable importance as out of pocket costs continue to rise in the US.

The Prometra II offers a pressure-driven, valve-gated delivery mechanism that allows for novel programming modes of intermittent flow followed by periods of no flow—a feature unique to this device.

The announcement formally connects Bcureful and the Tuberous Sclerosis Alliance together after working closely together for over the past 8 years.

The associate professor of neurology and director of the Women With Epilepsy Program at Northwestern University Feinberg School of Medicine discussed the reasons an adult with epilepsy may seek genetic testing and what benefits it can provide.

The chief medical officer of ProMIS Neurosciences comments on how aducanumab will help propel innovation needed to drive the next generation of therapies for Alzheimer disease.

Patients with Parkinson disease with moderate to severe white matter hyperintensity (WMH) burden had a greater risk of developing levodopa-induced dyskinesia compared with those with minimal WMHs.

Good functional recovery at 3 months is achieved in approximately a quarter of patients with acute ischemic stroke with large-vessel occlusion due to calcified emboli.

The chronic migraine preventive, despite falling short of efficacy end points, was safe and well-tolerated in a small cohort of patients aged 12 to 17 years.

The revision accounts for data from the NURTURE trial showing that patients with 3 copies of SMN2 greatly benefit from early treatment.

Patients with Huntington disease who received antihypertensive medication had slower disease progression less cognitive impairment compared with patients with untreated hypertension.

The Tuberous Sclerosis Alliance has announced updates to access of everolimus, a drug used to treat several conditions associated with tuberous sclerosis complex.

The vice president of Medical Affairs at Adamas Pharmaceuticals discussed the context of these results and what the clinical community should take away from the data from the EASE LID 2 trial of amantadine (Gocovri).

The DWI-based hierarchic algorithm predicted the risk of disability at 3 months for up to 100% of patients with a high predictive value.

The associate professor of neurology and director of the Women With Epilepsy Program at Northwestern University Feinberg School of Medicine spoke about the evolving landscape of the use of genetic tools in epilepsy.

This novel trial’s positive outcome suggests that a multidisciplinary outpatient model is possible to integrate into care beyond just those who are most vulnerable in institutional care.

Neurology News Network for the week ending February 15, 2020.